<DOC>
	<DOCNO>NCT00054353</DOCNO>
	<brief_summary>This phase I/II trial study side effect give reduced-intensity conditioning follow donor peripheral blood stem cell transplant ( PBSCT ) well work treat patient multiple myeloma ( MM ) . Giving low dos chemotherapy , fludarabine phosphate melphalan , total-body irradiation ( TBI ) donor PBSCT help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving mycophenolate mofetil cyclosporine transplant may stop happening .</brief_summary>
	<brief_title>Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate efficacy approach determine 1-year progression-free survival ( PFS ) overall survival ( OS ) . II . To evaluate day 100 non-relapse mortality . III . To determine incidence grade II-IV acute graft-versus-host disease ( GVHD ) chronic extensive GVHD . OUTLINE : PREPARATIVE REGIMEN : Patients receive fludarabine phosphate intravenously ( IV ) 30 minute day -5 -3 intermediate-dose melphalan IV 15-20 minute day -2 . Patients also undergo low-dose TBI day 0 . TRANSPLANTATION : Patients undergo allogeneic PBSCT day 0 . IMMUNOSUPPRESSION : Patients receive cyclosporine orally ( PO ) twice daily ( BID ) day -3 80 taper day 180 ( related donor ) day -3 100 taper day 180 ( unrelated donor ) . Patients also receive mycophenolate mofetil PO BID day 0-27 ( related donor ) thrice daily ( TID ) day 0-40 taper day 96 ( unrelated donor ) . After completion study treatment , patient follow 3 , 6 , 12 , 18 , 24 month , annually thereafter 5 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Meet Salmon Durie criterion initial diagnosis MM ; transplant offer patient previously treat MM meet one follow criterion : Patient receive least one prior autologous syngeneic hematopoietic SCT ( HSCT ) progressive disease ( PD ) ( great 25 % increase serum urine paraprotein level compare best response status autograft appearance new lytic bone lesion plasmocytomas ) Patient able collect autologous PBSC due poor marrow reserve ( insufficient HSCmobilization : &lt; 2.5 x 10^6 cluster differentiation [ CD ] 34+ cells/kg ) ; contraindication undergo HSCmobilization ; patient PD receive least 4 cycle standard chemotherapy ( e.g . vincristine sulfate , doxorubicin hydrochloride , dexamethasone [ VAD ] ) past Patients must capacity give informed consent DONOR : Human leukocyte antigen ( HLA ) genotypically identical sibling phenotypically match relative DONOR : HLA phenotypically match unrelated donor ( accord Standard Practice HLA match criterion ) Matched serologically recognize HLAA B C antigens least five six HLAA B C allele Matched HLA DRB1 DQB1 allele ( define highresolution type ) allele level DONOR : Donor must consent filgrastim ( GCSF ) administration leukapheresis PBSC collection DONOR : Donor must adequate vein leukapheresis agree placement temporary central venous catheter Karnofsky score &lt; 60 % Left ventricular ejection fraction &lt; 40 % symptomatic heart failure ; ejection fraction require age &gt; 50 year history anthracycline exposure history cardiac disease Patients clinical laboratory evidence liver disease would evaluate cause liver disease , clinical severity term liver function , degree portal hypertension ; patient exclude find fulminant liver failure , cirrhosis liver evidence portal hypertension , alcoholic hepatitis , esophageal varix , history bleed esophageal varix , hepatic encephalopathy , uncorrectable hepatic synthetic dysfunction evince prolongation prothrombin time , ascites related portal hypertension , bridge fibrosis , bacterial fungal liver abscess , biliary obstruction , chronic viral hepatitis total serum bilirubin &gt; 3 mg/dL , symptomatic biliary disease Diffusion capacity carbon monoxide ( DLCO ) &lt; 50 % ( correct ) receive continuous supplemental oxygen Creatinine clearance &lt; 40 mL/min Patients poorly control hypertension Seropositive human immunodeficiency virus ( HIV ) Patients history nonhematologic malignancy ( except nonmelanoma skin cancer ) currently complete remission , less 5 year time complete remission , &gt; 20 % risk disease recurrence Pregnancy breastfeed Fertile men woman unwilling use contraceptive technique 12 month follow treatment Not fully recover previous highdose therapy : Persistent mucositis gastrointestinal symptom require hyperalimentation and/or intravenous hydration On steroid autologous/syngeneic GVHD On IV antibiotic document infection Cytomegalovirus ( CMV ) antigenemia positive On ganciclovir foscarnet previous CMV reactivation/infection ; therapy less two week despite documented CMVantigenemia negativity ( identification [ ID ] consult persistent CMV antigenemia post autograft ) Ongoing radiotherapy Patients meet criterion may discuss principal investigator recommendation time allograft Patients active bacterial fungal infection unresponsive medical therapy DONOR : Identical twin DONOR : Donors unwilling donate PBSC DONOR : Pregnancy DONOR : Infection HIV DONOR : Inability achieve adequate venous access DONOR : Known allergy GCSF DONOR : Current serious systemic illness DONOR : Failure meet Fred Hutchinson Cancer Research Center ( FHCRC ) criteria stem cell donation DONOR : Age &lt; 12 year DONOR : A positive antidonor cytotoxic crossmatch absolute donor exclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>